Sensitivity of human meningioma cells to ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, tg02
Author(s) :
Von Achenbach, Caroline [Auteur]
University hospital of Zurich [Zurich]
Le Rhun, Emilie [Auteur]
University hospital of Zurich [Zurich]
Sahm, Felix [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Wang, Sophie S. [Auteur]
University hospital of Zurich [Zurich]
Sievers, Philipp [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Neidert, Marian Christoph [Auteur]
University hospital of Zurich [Zurich]
Rushing, Elisabeth J. [Auteur]
University hospital of Zurich [Zurich]
Lawhon, Tracy [Auteur]
Schneider, Hannah [Auteur]
University hospital of Zurich [Zurich]
Von Deimling, Andreas [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]
University hospital of Zurich [Zurich]
Le Rhun, Emilie [Auteur]
University hospital of Zurich [Zurich]
Sahm, Felix [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Wang, Sophie S. [Auteur]
University hospital of Zurich [Zurich]
Sievers, Philipp [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Neidert, Marian Christoph [Auteur]
University hospital of Zurich [Zurich]
Rushing, Elisabeth J. [Auteur]
University hospital of Zurich [Zurich]
Lawhon, Tracy [Auteur]
Schneider, Hannah [Auteur]
University hospital of Zurich [Zurich]
Von Deimling, Andreas [Auteur]
German Cancer Consortium [Heidelberg] [DKTK]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] [DKFZ]
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]
Journal title :
Translational Oncology
Abbreviated title :
Transl Oncol
Volume number :
13
Pages :
100852
Publisher :
Elsevier
Publication date :
2020-09-08
ISSN :
1944-7124
English keyword(s) :
Methylation
TG02
Meningioma
Mutation
TG02
Meningioma
Mutation
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Standards of care for meningioma include surgical resection and radiotherapy whereas pharmacotherapy plays almost no role in this disease. We generated primary cultures from surgically removed meningiomas to explore the ...
Show more >Standards of care for meningioma include surgical resection and radiotherapy whereas pharmacotherapy plays almost no role in this disease. We generated primary cultures from surgically removed meningiomas to explore the activity of a novel cyclin-dependent kinase inhibitor, TG02, in meningioma cell cultures. Tumor and cell cultures were characterized by mutation profiling and DNA methylation profiling. DNA methylation data were used to allot each sample to one out of six previously established meningioma methylation classes: benign (ben)-1, 2, 3, intermediate (int)-A, B, and malignant (mal). Four tumors assigned to the methylation class ben-2 showed the same class in culture whereas cultures from five non-ben-2 tumors showed a more malignant class in four patients. Cell cultures were uniformly sensitive to TG02 in the nanomolar range. Assignment of the cell cultures to a more malignant methylation class appeared to be more closely associated with TG02 sensitivity than assignment to a higher WHO grade of the primary tumors. Primary cell cultures from meningioma facilitate the investigation of the anti-meningioma activity of novel agents. TG02, an orally available cyclin-dependent kinase (CDK) inhibitor, warrants further exploration.Show less >
Show more >Standards of care for meningioma include surgical resection and radiotherapy whereas pharmacotherapy plays almost no role in this disease. We generated primary cultures from surgically removed meningiomas to explore the activity of a novel cyclin-dependent kinase inhibitor, TG02, in meningioma cell cultures. Tumor and cell cultures were characterized by mutation profiling and DNA methylation profiling. DNA methylation data were used to allot each sample to one out of six previously established meningioma methylation classes: benign (ben)-1, 2, 3, intermediate (int)-A, B, and malignant (mal). Four tumors assigned to the methylation class ben-2 showed the same class in culture whereas cultures from five non-ben-2 tumors showed a more malignant class in four patients. Cell cultures were uniformly sensitive to TG02 in the nanomolar range. Assignment of the cell cultures to a more malignant methylation class appeared to be more closely associated with TG02 sensitivity than assignment to a higher WHO grade of the primary tumors. Primary cell cultures from meningioma facilitate the investigation of the anti-meningioma activity of novel agents. TG02, an orally available cyclin-dependent kinase (CDK) inhibitor, warrants further exploration.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
INSERM
Université de Lille
Université de Lille
Collections :
Submission date :
2022-06-15T13:57:59Z
2023-03-07T09:54:28Z
2023-03-07T09:54:28Z
Files
- 2020-09-08-1-s2.0-S1936523320303442-main.pdf
- Version éditeur
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States